*Correctly identified as negative for breast cancer 80 per cent of patients referred for a biopsy as a result of mammography. This highlights the potential value of the test in conjunction with current screening methods
and
*13 patients found to be positive for breast cancer by a mammogram and biopsy were missed by the Fermiscan test. This is believed to be due to damage to hair from treatments not identified by fluorescence screening and/or biological variation. The accuracy of the test can be affected by hair treatments such as perming, dyeing and straightening, which can be overcome in most cases by using new growth of the hair (approximately 4 weeks required)
Means that one it works and two with a little management, the accuracy of the test should be better.
Commercialisation in Aus to commence this year - good news!
*Fermiscan plans to gather data from patients with a range of breast cancers (and other cancer patients) to allow further refinement and improvement of the test
Does this means they are also look at expanding it beyond just breast cancer and seeing if it works for other types of cancer? If so, potential for more good news (and share price appreciation).
FER Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
